US FDA Grants Fast-Track Designation to BioVersys for BV100

On September 2, 2026, BioVersys AG, a biopharmaceutical company based in Basel, Switzerland, announced that the U.S. FDA has granted Fast Track Designation to its lead clinical asset, BV100. This designation is intended to accelerate the development of treatments for serious infections caused by carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC).

BV100, an intravenous formulation of rifabutin, is under evaluation in Phase 3 trials for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia. The Fast Track status will facilitate more frequent FDA interactions, potentially expediting BV100's review process.

CRABC remains a critical health challenge globally, with mortality rates reaching 50%. The novel approach of BV100 aims to address this urgent medical need, offering hope for patients with severe multidrug-resistant infections.